...
首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >NOVEL NANOPARTICLES FOR THE ORAL DELIVERY OF LOW MOLECULAR WEIGHT HEPARIN: IN VITRO AND IN VIVO ASSESSMENT
【24h】

NOVEL NANOPARTICLES FOR THE ORAL DELIVERY OF LOW MOLECULAR WEIGHT HEPARIN: IN VITRO AND IN VIVO ASSESSMENT

机译:低分子肝素口服给药的新型纳米颗粒:体外和体内评估

获取原文
           

摘要

Objective: The objective of the present study was to prepare and evaluate a novel oral formulation of nanoparticles for the systemic delivery of low molecular weight heparin (LMWH). Methods: Nanoparticles were prepared by polyelectrolyte complexation (PEC) method using polymers sodium alginate and chitosan. Entrapment efficiency of LMWH in nanoparticles was found to be ?88%. Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), X?ray diffraction (XRD), Scanning electron microscopy (SEM) studies carried for nanoparticles. In vitro release studies were performed for the formulations. Ex vivo permeation studies were performed optimized formulation by using small intestine of rat and in vivo studies were conducted on rat model. Results: In vitro release studies demonstrated that the release of LMWH was negligible in the stomach and high in the small intestine. FTIR has indicated that there is no interaction between the ingredients in nanoparticle. DSC and XRD studies confirmed that the amino groups of chitosan interacted with the carboxylic groups of alginate. Invitro % drug release of 95% was shown by formulation AC5. Ex vivo permeation studies have elucidated that ? 73% of LMWH was transported across the epithelium. Nanoparticles have shown enhanced oral bioavailability of LMWH as revealed by 4.5 fold increase in AUC of plasma drug concentration time curve. Conclusion: The results suggest that the nanoparticles prepared can result in targeted delivery of LMWH into systemic circulation via intestinal and colon routes. Novel nanoparticles thus prepared in this study can be considered as a promising delivery system.
机译:目的:本研究的目的是制备和评估新型的纳米颗粒口服制剂,用于全身性递送低分子量肝素(LMWH)。方法:利用聚合物海藻酸钠和壳聚糖通过聚电解质络合(PEC)方法制备纳米粒子。发现LMWH在纳米颗粒中的包封率为〜88%。纳米粒子的傅里叶变换红外光谱(FTIR),差示扫描量热法(DSC),X射线衍射(XRD),扫描电子显微镜(SEM)研究。对制剂进行了体外释放研究。通过使用大鼠的小肠进行离体渗透研究,以优化配方,并在大鼠模型上进行体内研究。结果:体外释放研究表明,LMWH在胃中的释放微不足道,而在小肠中的释放高。 FTIR表明纳米颗粒中的成分之间没有相互作用。 DSC和XRD研究证实壳聚糖的氨基与藻酸盐的羧基相互作用。制剂AC5显示95%的体外药物释放%。离体渗透研究阐明了这一点? 73%的LMWH跨上皮运输。纳米颗粒已显示出LMWH的口服生物利用度增强,如血浆药物浓度时间曲线的AUC增加了4.5倍。结论:结果表明,所制备的纳米颗粒可通过肠和结肠途径将LMWH靶向递送至全身循环。在这项研究中由此制备的新型纳米颗粒可以被认为是有希望的递送系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号